ReviewLife (Basel, Switzerland)2023
Centralized and Interdisciplinary Therapy Management in the Treatment of Sarcomas.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Enhancing Precision in Pelvic Tumor Reconstruction: Early Experience and Iterative Design of Custom 3D-Printed Implants.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026Article
- Local Recurrence and Metastasis Define Distinct Recurrence Phenotypes in Soft Tissue Sarcoma.Cancers · 2026Article
- Review
- The role of plastic reconstructive surgery in surgical reconstruction of soft tissue defects after resection of musculoskeletal tumors.JPRAS open · 2026Article
- The imitation game: large language models versus multidisciplinary tumor boards: benchmarking AI against 21 sarcoma centers from the ring trial.Journal of cancer research and clinical oncology · 2025Article
- Stepwise Surgical Strategy for Retroperitoneal Myxofibrosarcoma with Inferior Vena Cava Reconstruction Prior to En Bloc Resection: A Case Report.Vascular specialist international · 2025Article
- Therapy adherence after interdisciplinary tumour board discussion is associated with improved outcome in soft tissue sarcoma: A Charité Comprehensive Cancer Centre analysis.International journal of cancer · 2025Article
- Osteosarcoma Management in the Precision Medicine Era: Bibliometric Analysis and Clinical Progress (2015-2024).The archives of bone and joint surgery · 2025Review
- Ewing Sarcoma in the Pediatric Population: Predictors of Survival Within the United States.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2024Article
- Giant Myxofibrosarcoma in the Lower Limb: An Overview of Diagnostic and Clinical Management.Diagnostics (Basel, Switzerland) · 2024Review
- Artificial intelligence large language model ChatGPT: is it a trustworthy and reliable source of information for sarcoma patients?Frontiers in public health · 2024Article
- Best Practices for the Management of Patients with Non-Tuberculous Mycobacterial Pulmonary Disease According to a German Nationwide Analysis of Expert Centers.Healthcare (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoma treatment requires a high level of expertise due to its rarity and heterogeneity. Sarcoma patients should, therefore, be referred to an expert centre as early as possible to ensure optimal treatment. Numerous studies have been carried out to provide evidence for this strategy. In compliance with the 2020 PRISMA guidelines, a systematic search was conducted in PubMed, EMBASE, Ovid Medline, ClinicalTrials.gov and Cochrane Library databases. The subject of these studies was the centralised treatment of adult sarcoma patients at expert centres and the use of interdisciplinary tumour boards. Uncertainty in therapy, delays in referral to expert centres, and limited access to therapeutic modalities continue to be a challenge in sarcoma therapy. At expert centres, diagnostic procedures were more frequently and adequately performed, and treatment was associated with an improvement in outcomes in the majority of studies: patients benefited from longer survival, lower local recurrence rates and a better postoperative outcome. The implementation of an interdisciplinary tumour board was associated with discrepant results. In a greater number of studies, it was associated with a lower local relapse rate, better overall survival and surgical outcome. In two studies, however, a shorter overall survival was observed. The establishment of expert centres and the consistent use of interdisciplinary tumour boards are important structures for ensuring multidisciplinary therapy approaches. There is growing evidence that this holds great potential for optimising sarcoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.